Apollo Health Ventures
Transatlantic early-stage venture capital firm that co-founds and invests in biotechnology and health-technology companies targeting aging and age-related diseases. Uses a combination of venture building (Venture Lab) and external early-stage investments to develop therapeutics, data platforms and health tech with the objective of impacting human health within the next decade.
Industries
Nr. of Employees
small (1-50)
Apollo Health Ventures
Apollo Ventures Holding GmbH, Große Reichenstraße 27, 20457 Hamburg
Portfolio
Closed a $50M follow-on round and is moving towards human clinical trials (news March 2024).
#Pharmaceuticals / therapeutics
Secured Series A financing ($48M in 2022), FDA clearances, Fast Track designation and a $27M Series B (2025); developing an AI-powered multi-omics platform (AURIGIN™).
#Precision oncology / targeted cancer therapeutics
Published positive topline data from a Phase 1 clinical trial for BL-001 (Dravet syndrome and ALS).
#Therapeutics (neurology)
Launched with $15M seed financing led by Apollo Health Ventures and Novo Holdings (Oct 2024).
#Therapeutics (proteasome activator medicines)
Raised $2.5M seed financing to advance FOXO4-therapeutics for cancer and chronic diseases (Sept 2022).
#Biotech / therapeutics
Launched as a new cellular reprogramming startup in partnership with Paul Scherrer Institute (Oct 2022).
#Cellular reprogramming / regenerative biotech
Closed a $50M follow-on round and is moving towards human clinical trials (news March 2024).
#Pharmaceuticals / therapeutics
Secured Series A financing ($48M in 2022), FDA clearances, Fast Track designation and a $27M Series B (2025); developing an AI-powered multi-omics platform (AURIGIN™).
#Precision oncology / targeted cancer therapeutics
Published positive topline data from a Phase 1 clinical trial for BL-001 (Dravet syndrome and ALS).
#Therapeutics (neurology)
Launched with $15M seed financing led by Apollo Health Ventures and Novo Holdings (Oct 2024).
#Therapeutics (proteasome activator medicines)
Raised $2.5M seed financing to advance FOXO4-therapeutics for cancer and chronic diseases (Sept 2022).
#Biotech / therapeutics
Launched as a new cellular reprogramming startup in partnership with Paul Scherrer Institute (Oct 2022).
#Cellular reprogramming / regenerative biotech